Most recently, the HERO phase III trial randomly assigned men with advanced prostate cancer to the GnRH agonist relugolix vs leuprolide and found that the 48-week cumulative incidence of MACE was statistically significant reduced from 6.2% to 2.9% (hazard ratio = 0.46). This evidence concerns the gene GNRH1 and prostate carcinoma.